Related Experiment Video
Updated: Apr 30, 2026
Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions
Published on: April 23, 2021
Cerebral microbleeds as a predictor of macrobleeds: what is the evidence?
Andreas Charidimou1, David J Werring
1Stroke Research Group, UCL Institute of Neurology and The National Hospital for Neurology and Neurosurgery, Queen Square, London, UK.
Abstract:
Cerebral microbleeds on blood-sensitive magnetic resonance imaging sequences have emerged as a common and important marker of small vessel disease. Cerebral microbleeds differ from other imaging manifestations of small vessel disease (e.g. lacunes and leukoaraiosis), as they seem to provide more direct evidence of microvascular leakiness from bleeding-prone arteriopathies, namely hypertensive arteriopathy and cerebral amyloid angiopathy, the two leading causes of spontaneous intracerebral haemorrhage. Thus, cerebral microbleeds in specific sub-populations might provide evidence of an ongoing active small vessel arteriopathy with increased future risk of symptomatic intracerebral haemorrhage ('macrobleeding'). If this hypothesis is correct, it raises clinical dilemmas especially regarding the safety of antithrombotic drug use. Although data so far are limited, the relationship of microbleeds to future macrobleeding (and cerebral ischemia) seems to critically depend on the specific patient population and cerebral microbleeds location and burden, which may reflect the nature and severity of the underlying arteriopathies.
Insights
Cerebral microbleeds, visible on MRI, indicate small vessel disease and bleeding risks. Their presence and location may predict future hemorrhage, impacting antithrombotic drug safety.
Area of Science:
- Neurology
- Radiology
- Vascular Medicine
Background:
- Cerebral microbleeds (CMBs) are key markers of small vessel disease (SVD) detected via blood-sensitive MRI.
- CMBs signify microvascular leakage from arteriopathies like hypertensive arteriopathy and cerebral amyloid angiopathy, major causes of intracerebral hemorrhage.
- Unlike lacunes or leukoaraiosis, CMBs offer direct evidence of active microvascular pathology.
Purpose of the Study:
- To explore the clinical significance of CMBs as indicators of active SVD.
- To investigate the potential link between CMBs and the future risk of symptomatic intracerebral hemorrhage (macrobleeding).
- To address the clinical implications of CMBs for antithrombotic drug safety.
Main Methods:
- Utilizing blood-sensitive magnetic resonance imaging (MRI) sequences to identify cerebral microbleeds.
- Analyzing patient populations to correlate CMB presence, location, and burden with underlying arteriopathies.
- Reviewing existing data on the relationship between CMBs and future macrobleeding or cerebral ischemia events.
Main Results:
- CMBs appear to be a direct indicator of microvascular leakiness in specific arteriopathies.
- The presence of CMBs may signal an increased risk of future symptomatic intracerebral hemorrhage in certain patient groups.
- The association between CMBs and future bleeding or ischemic events is influenced by patient population, CMB location, and burden.
Conclusions:
- Cerebral microbleeds are crucial imaging biomarkers reflecting active small vessel arteriopathies.
- CMBs may predict future macrobleeding risk, posing challenges for antithrombotic therapy decisions.
- Further research is needed to fully elucidate the relationship between CMBs, arteriopathies, and clinical outcomes.
Related Concept Videos
01:17Hemorrhagic Stroke l: Introduction
01:22Cerebral Edema ll: Pathophysiology
01:29Hemorrhagic Stroke ll: Pathophysiology